Dow strengthens drug solubility enhancement portfolio

摘要

Dow Pharma & Food Solutions, a business unit of Dow Chemical, announced strengthening of its 'Affinisol' drug solubility enhancement portfolio. The commercial viability of a pharmaceutical product is linked to the oral bioavailability of the active ingredient, which is severely limited by the compound's aqueous solubility; and the majority of New Chemical Entities in drug development pipelines fall into this category. Dow's 'Affinisol' range are aimed at addressing the solubility challenges in spray dried dispersion (SDD) and hot melt extrusion (HMF.) formulations.